167 related articles for article (PubMed ID: 11879248)
1. Does treatment modality have an impact on anemia in patients with chronic renal failure? Effect of low- and high-flux biocompatible dialysis.
Opatrný K; Reischig T; Vienken J; Eiselt J; Vít L; Opatrná S; Sefrna F; Racek J; Brown GS
Artif Organs; 2002 Feb; 26(2):181-8. PubMed ID: 11879248
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of the hemodialysis adequacy conducted based on low-flux polysulfone dialyzers and high-flux helixone dialyzers].
Sobaszek-Pitas M; Kopeć J; Krzanowski M; Sułowicz W
Przegl Lek; 2014; 71(7):384-8. PubMed ID: 25338334
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of the iron metabolism and effectiveness of anemia treatment in patients on maintenance hemodialysis performed based on polysulfone and helixone dialyzers].
Sobaszek-Pitas M; Krzanowska K; Sułowicz W
Przegl Lek; 2014; 71(8):418-22. PubMed ID: 25546912
[TBL] [Abstract][Full Text] [Related]
4. Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients.
Movilli E; Cancarini GC; Zani R; Camerini C; Sandrini M; Maiorca R
Nephrol Dial Transplant; 2001 Jan; 16(1):111-4. PubMed ID: 11209002
[TBL] [Abstract][Full Text] [Related]
5. A randomized, controlled study of the consequences of hemodialysis membrane composition on erythropoietic response.
Richardson D; Lindley EJ; Bartlett C; Will EJ
Am J Kidney Dis; 2003 Sep; 42(3):551-60. PubMed ID: 12955684
[TBL] [Abstract][Full Text] [Related]
6. Epoetin requirement does not depend on dialysis dose when Kt/N > 1.33 in patients on regular dialysis treatment with cellulosic membranes and adequate iron stores.
Movilli E; Cancarini GC; Vizzardi V; Camerini C; Brunori G; Cassamali S; Maiorca R
J Nephrol; 2003; 16(4):546-51. PubMed ID: 14696757
[TBL] [Abstract][Full Text] [Related]
7. Are high flux dialysis and erythropoietin treatment in a collision course?
Acchiardo SR; Quinn BP; Burk LB; Moore LW
ASAIO Trans; 1989; 35(3):308-10. PubMed ID: 2688711
[TBL] [Abstract][Full Text] [Related]
8. Residual blood loss in single use dialyzers: effect of different membranes and flux.
Kalocheretis P; Vlamis I; Belesi C; Makriniotou I; Zerbala S; Savidou E; Zorbas S; Arvanitis N; Iatrou C
Int J Artif Organs; 2006 Mar; 29(3):286-92. PubMed ID: 16685672
[TBL] [Abstract][Full Text] [Related]
9. Improved preservation of residual renal function in chronic hemodialysis patients using polysulfone dialyzers.
McCarthy JT; Jenson BM; Squillace DP; Williams AW
Am J Kidney Dis; 1997 Apr; 29(4):576-83. PubMed ID: 9100048
[TBL] [Abstract][Full Text] [Related]
10. The effect of high-flux hemodialysis on renal anemia.
Ayli D; Ayli M; Azak A; Yüksel C; Kosmaz GP; Atilgan G; Dede F; Abayli E; Camlibel M
J Nephrol; 2004; 17(5):701-6. PubMed ID: 15593038
[TBL] [Abstract][Full Text] [Related]
11. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
12. [Comparative analysis of the efficacy and biocompatibility of various methods of dialysis].
Zivanović M; Hrvacević R; Kovacević Z; Veljancić L; Vujanić S
Vojnosanit Pregl; 2005 Oct; 62(10):725-9. PubMed ID: 16305099
[TBL] [Abstract][Full Text] [Related]
13. Assessment of subjective and hemodynamic tolerance of different high- and low-flux dialysis membranes in patients undergoing chronic intermittent hemodialysis: a randomized controlled trial.
Bianchi G; Salvadé V; Lucchini B; Schätti-Stählin S; Salvadé I; Burnier M; Gabutti L
Hemodial Int; 2014 Oct; 18(4):825-34. PubMed ID: 24865782
[TBL] [Abstract][Full Text] [Related]
14. Bisphenol A in chronic kidney disease.
Krieter DH; Canaud B; Lemke HD; Rodriguez A; Morgenroth A; von Appen K; Dragoun GP; Wanner C
Artif Organs; 2013 Mar; 37(3):283-90. PubMed ID: 23145999
[TBL] [Abstract][Full Text] [Related]
15. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
[TBL] [Abstract][Full Text] [Related]
16. Dialyzer Reuse and Outcomes of High Flux Dialysis.
Argyropoulos C; Roumelioti ME; Sattar A; Kellum JA; Weissfeld L; Unruh ML
PLoS One; 2015; 10(6):e0129575. PubMed ID: 26057383
[TBL] [Abstract][Full Text] [Related]
17. Results from EuCliD (European Clinical Dialysis Database): impact of shifting treatment modality.
Merello Godino JI; Rentero R; Orlandini G; Marcelli D; Ronco C
Int J Artif Organs; 2002 Nov; 25(11):1049-60. PubMed ID: 12487392
[TBL] [Abstract][Full Text] [Related]
18. [Beneficial effect of AN69 membranes on anemia in hemodialyzed patients].
García Cortés MJ; Sánchez Perales MC; Liébana A; Gil JM; Borrego FJ; Borrego J; Pérez del Barrio P; Serrano P; Pérez Bañasco V
Nefrologia; 2001; 21(4):370-5. PubMed ID: 11816513
[TBL] [Abstract][Full Text] [Related]
19. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.
Ifudu O; Feldman J; Friedman EA
N Engl J Med; 1996 Feb; 334(7):420-5. PubMed ID: 8552143
[TBL] [Abstract][Full Text] [Related]
20. Application of cystatin C reduction ratio to high-flux hemodialysis as an alternative indicator of the clearance of middle molecules.
Park JS; Kim GH; Kang CM; Lee CH
Korean J Intern Med; 2010 Mar; 25(1):77-81. PubMed ID: 20195407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
